News
2020
Joining in LifeBridge Health BioIncubator!
2021
PZA innovation has a peer reviewed publication:
Shi, W. Activity of Pyrazinamide against Mycobacterium tuberculosis at
Neutral pH in PZA-S1 Minimal Medium. Antibiotics 2021, 10, 909.
https://doi.org/10.3390/antibiotics10080909
2022
On Jan. 1st 2022, The National Science Foundation (NSF) awarded PZA innovation LLC a Small Business Innovation Research (SBIR) Phase I grant (Award ID: 2136133) to develop reliable pyrazinamide susceptibility testing.
2023
On Nov. 20, 2023, PZA Innovation LLC was awarded the MBIA Commercialization Impact Grant for FY24 to support its business growth and innovation.
2024
On Jan. 2nd, 2024, PZA Innovation LLC has been awarded a $1.68 million Direct to SBIR Phase II Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). This grant supports the project titled ‘Development of a Rapid Phenotypic Pyrazinamide Susceptibility Testing Using a Well-Standardized Protocol’ (Grant Number: R44AI181252) over two years.
The funding will drive Research & Development efforts to improve the reliability and speed of Pyrazinamide susceptibility testing for tuberculosis (TB) while facilitating commercialization. Working in collaboration with two institutes, the project aims to address systemic issues and limitations in current methods. This advancement promises to enhance TB treatment by providing patients with the most effective treatment and curbing TB drug resistance.
2025
PZA Innovation LLC Co-Authors Landmark Publication in Frontiers in Microbiology on Neutral-pH Determination of PZA MICs in Mycobacterium tuberculosis Clinical Isolates
PZA Innovation LLC is proud to announce the publication of a new peer-reviewed study in Frontiers in Microbiology (October 20, 2025; Volume 16), titled: “Determining the minimum inhibitory concentrations of pyrazinamide against Mycobacterium tuberculosis clinical isolates at a neutral pH of 6.8 using the broth microdilution method.” DOI: https://doi.org/10.3389/fmicb.2025.1688772
